人工智慧（AI）联合研究与授权协议（2019-2024）

本报告审查了人工智慧研究合作和授权协议，以详细瞭解和分析了公司如何以及为何签订人工智慧协议。

目录

执行摘要

第1章简介

第2章 人工智慧合约趋势

• 介绍
• 过去几年的人工智慧合约
• 最活跃的人工智慧承包公司
• 人工智慧合约：按合约类型
• AI 合约：按治疗领域
• 人工智慧合约：按行业分类
• 人工智慧合约条款和条件
  • AI合约标题金额
  • AI合约预付款
  • AI合约里程碑付款
  • 人工智慧使用费率

第3章 主要人工智慧合约

• 介绍
• 按价值排名最高的人工智慧合约

第 4 章：最活跃的人工智慧承包商

• 介绍
• 最活跃的人工智慧承包公司
• 最活跃的人工智慧承包公司概况

第5章 AI合约目录

• 介绍
• AI合约目录

第6章 人工智慧合约：依技术类型

• 合约目录
• 合约目录 - AI 合约：按公司 (AZ)
• 合约目录 - AI 合约：依合约类型
• 合约目录 - AI 合约：依治疗领域
• 定义合约类型
• 关于Biopharma Research Ltd
• 目前的合作伙伴
• 目前协议
• 目前合作伙伴最近报告的标题

Artificial Intelligence (AI) Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the artificial intelligence deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of artificial intelligence deals from 2019 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter artificial intelligence deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 887 artificial intelligence deals announced since 2019 including financial terms where available including links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of artificial intelligence dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in artificial intelligence dealmaking since 2019.

Chapter 3 provides an overview of the leading artificial intelligence deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in artificial intelligence dealmaking with a brief summary followed by a comprehensive listing of artificial intelligence deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of artificial intelligence deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan 2019. The chapter is organized by specific artificial intelligence technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in artificial intelligence deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Artificial Intelligence (AI) Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2019
• Browse artificial intelligence collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Artificial Intelligence (AI) Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of artificial intelligence trends and structure of deals entered into by leading biopharma companies worldwide.

Artificial Intelligence (AI) Collaboration and Licensing Deals includes:

• Trends in artificial intelligence dealmaking in the biopharma industry
• Directory of artificial intelligence deal records covering pharmaceutical and biotechnology
• The leading artificial intelligence deals by value
• Most active artificial intelligence licensing dealmakers
• Artificial Intelligence (AI) Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in artificial intelligence dealmaking

• 2.1. Introduction
• 2.2. Artificial intelligence deals over the years
• 2.3. Most active artificial intelligence dealmakers
• 2.4. Artificial intelligence deals by deal type
• 2.5. Artificial intelligence deals by therapy area
• 2.6. Artificial intelligence deals by industry sector
• 2.7. Deal terms for artificial intelligence deals
  • 2.7.1 Artificial intelligence deals headline values
  • 2.7.2 Artificial intelligence deal upfront payments
  • 2.7.3 Artificial intelligence deal milestone payments
  • 2.7.4 Artificial intelligence royalty rates

Chapter 3 - Leading artificial intelligence deals

• 3.1. Introduction
• 3.2. Top artificial intelligence deals by value

Chapter 4 - Most active artificial intelligence dealmakers

• 4.1. Introduction
• 4.2. Most active artificial intelligence dealmakers
• 4.3. Most active artificial intelligence deals company profiles

Chapter 5 - Artificial intelligence contracts dealmaking directory

• 5.1. Introduction
• 5.2. Artificial intelligence contracts dealmaking directory

Chapter 6 - Artificial intelligence dealmaking by technology type

• Deal directory
• Deal directory - Artificial intelligence deals by company A-Z
• Deal directory - Artificial intelligence deals by deal type
• Deal directory - Artificial intelligence deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Artificial intelligence deals since 2019
• Figure 2: Active artificial intelligence dealmaking activity - 2019 - 2024
• Figure 3: Artificial intelligence deals by deal type since 2019
• Figure 4: Artificial intelligence deals by therapy area since 2019
• Figure 5: Artificial intelligence deals by industry sector since 2019
• Figure 6: Artificial intelligence deals with a headline value
• Figure 7: Artificial intelligence deals with an upfront value
• Figure 8: Artificial intelligence deals with a milestone value
• Figure 9: Artificial intelligence deals with a royalty rate value
• Figure 10: Top artificial intelligence deals by value since 2019
• Figure 11: Most active artificial intelligence dealmakers 2019 - 2024
• Figure 12: Artificial intelligence deals by technology type since 2019